Recent advances in mass spectrometry-based proteomics of gastric cancer

Kang, Changwon; Lee, Yejin; Lee, J Eugene

doi:10.3748/wjg.v22.i37.8283

Cited by 22 publications

(13 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Proteomics study around the protein biomarkers has indicated that some proteins might serve as the potential prognostic biomarker (19)(20)(21). It has been revealed that IGFBPs, specifically IGFBP-3, could be considered as a potential prognostic biomarker (22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer

Ansari¹,

Gheysarzadeh²,

Bakhtiari³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gastric cancer (GC) as one of the most common cancers, serves as the third cause of cancer-related death. Insulin-like growth factor binding protein 3 (IGFBP-3) and its novel death receptor (IGFBP-3R) has been shown to have an anti-tumor effect however their prognostic values have not been elucidated yet. Methods: IGFBP-3 and IGFBP-3R expression were evaluated with quantitative real-time polymerase chain reaction and western blotting in patients with GC (N=68). The relationship between prognostic factors such as tumor stage, tumor grade, tumor size, metastases, and Overall Survival (OS) with IGFBP-3/IGFBP-3R expression was also assessed. Results: IGFBP-3 and its death receptor expression were determined as dialectic evidence. In the experimental procedure, IGFBP-3 and IGFBP-3R expression were reduced in tumor tissues significantly. We found that there was an association between the reduction of IGFBP-3 with lymph node metastasis and TMN staging ( P<0.001 ). In addition, IGFBP-3R expression was associated with tumor size ( P=0.004 ), lymph node metastasis ( P<0.001 ), differentiation ( P=0.002 ) and TNM classification ( P=0.005 ). Interestingly, we presented that the downregulation of IGFBP-3R was stage-dependent. In OS analysis, we offered that low levels of IGFBP-3R mRNA expression were unfavorable with survival rate (P=0.002 ). IGFBP-3 regardless of its relationship with some prognostic parameters, there was no significant relationship between IGFBP-3 and OS. Conclusion: The findings of this study showed that IGFBP-3R has the potential to be a new prognostic biomarker of GC. But despite some benefit of IGFBP-3, it cannot be accepted as a prognostic biomarker. However, this finding must be improved and confirmed by future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer

Ansari¹,

Gheysarzadeh²,

Bakhtiari³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Gastric cancer has one of the highest mortality rates worldwide 86 , 87 urgently requiring its early detection 88 , 89 . Studies of gastric cancer biomarkers mainly focus on tissues 90 , blood 91 , and biological fluids to identify protein, RNA 92 , and DNA 93 .…”

Section: Application Of Ms In Cancer Biomarker Discoverymentioning

confidence: 99%

Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application

Huang¹,

Chen²,

He³

et al. 2017

Theranostics

View full text Add to dashboard Cite

There is a critical need for the discovery of novel biomarkers for early detection and targeted therapy of cancer, a major cause of deaths worldwide. In this respect, proteomic technologies, such as mass spectrometry (MS), enable the identification of pathologically significant proteins in various types of samples. MS is capable of high-throughput profiling of complex biological samples including blood, tissues, urine, milk, and cells. MS-assisted proteomics has contributed to the development of cancer biomarkers that may form the foundation for new clinical tests. It can also aid in elucidating the molecular mechanisms underlying cancer. In this review, we discuss MS principles and instrumentation as well as approaches in MS-based proteomics, which have been employed in the development of potential biomarkers. Furthermore, the challenges in validation of MS biomarkers for their use in clinical practice are also reviewed.

show abstract

“…Mass spectrometry (MS)-based techniques have become some of the most prevalently employed analytical strategies for the detection and identification of endogenous biomolecules in tissue. The application of these techniques is now commonplace in clinical research [ 3 , 4 , 5 ] and the mass spectrometric detection of pathologically significant molecules has already shown promise in the study of gastric cancer, providing greater insights into the molecular aspects of the disease and aiding in the identification of candidate biomarkers [ 6 ]. Furthermore, the emergence of modern mass spectrometry imaging (MSI) techniques has further revolutionised this area of research.…”

Section: Introductionmentioning

confidence: 99%

Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review

Smith

Piga

Galli

et al. 2017

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide and the disease outcome commonly depends upon the tumour stage at the time of diagnosis. However, this cancer can often be asymptomatic during the early stages and remain undetected until the later stages of tumour development, having a significant impact on patient prognosis. However, our comprehension of the mechanisms underlying the development of gastric malignancies is still lacking. For these reasons, the search for new diagnostic and prognostic markers for gastric cancer is an ongoing pursuit. Modern mass spectrometry imaging (MSI) techniques, in particular matrix-assisted laser desorption/ionisation (MALDI), have emerged as a plausible tool in clinical pathology as a whole. More specifically, MALDI-MSI is being increasingly employed in the study of gastric cancer and has already elucidated some important disease checkpoints that may help us to better understand the molecular mechanisms underpinning this aggressive cancer. Here we report the state of the art of MALDI-MSI approaches, ranging from sample preparation to statistical analysis, and provide a complete review of the key findings that have been reported in the literature thus far.

show abstract

Recent advances in mass spectrometry-based proteomics of gastric cancer

Cited by 22 publications

References 79 publications

Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer

Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer

Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application

Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review

Contact Info

Product

Resources

About